Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Non-Colorectal Indications

Current Problems in Cancer

Volumn 33, Issue 3, 2009, Pages 168-193

  Shen, Perry ^a   Stewart IV, John H ^a   Levine, Edward A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; IMATINIB; MITOMYCIN C; MITOXANTRONE; SODIUM THIOSULFATE;

ADOLESCENT; ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; COHORT ANALYSIS; COOLING; CYTOREDUCTIVE SURGERY; ENTEROCUTANEOUS FISTULA; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTHERMIC THERAPY; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; OPERATION DURATION; OVARY CANCER; PNEUMONIA; PROGNOSIS; RESPIRATORY FAILURE; SARCOMA; SEPSIS; SMALL INTESTINE CANCER; STOMACH CANCER; TEMPERATURE MEASUREMENT; TREATMENT DURATION; TREATMENT INDICATION; WOUND INFECTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67651253133     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2009.06.005     Document Type: Article

References (103)

1. Sadeghi B., Arvieux C., Glehen O., Beaujard A.C., Rivoire M., Baulieux J., et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88 (2000) 358-363
2. Sugarbaker P.H. Peritonectomy procedures. Ann Surg 221 (1995) 29-42
3. Torisu M., Katano M., Kimura Y., Itoh H., and Takesue M. New approach to management of malignant ascites with a streptococcal preparation OK 432. I. Improvement of host immunity and prolongation of survival. Surgery 93 (1983) 357-364
4. Hendren S.K., Hahn S.M., Spitz F.R., Bauer T.W., Rubin S.C., Zhu T., et al. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol 8 (2001) 65-71
5. Sindelar W.F., DeLaney T.F., Tochner Z., Thomas G.F., Dachoswki L.J., Smith P.D., et al. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms. Phase I study. Arch Surg 126 (1991) 318-324
6. Sugarbaker P.H., and Jablonski K.A. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221 (1995) 124-132
7. Beaujard A.C., Glehen O., Caillot J.L., Francois Y., Bienvenu J., Panteix G., et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 88 (2000) 2512-2519
8. Loggie B.W., Fleming R.A., McQuellon R.P., Russell G.B., and Geisinger K.R. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 66 (2000) 561-568
9. Verwaal V.J., van Ruth S., de Bree E., van Sloothen G.W., van Tinteren H., and Boot H. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21 (2003) 3737-3743
10. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
11. Markman M., and Walker J.L. Intraperitoneal chemotherapy in ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24 (2006) 988-994
12. Miner T.J., Shia J., Jaques D.P., Klimstra D.S., Brennan M.F., and Coit D.G. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241 (2005) 300-308
13. Gough D.B., Donohue J.H., Schutt A.J., Gonchoroff N., Goellner J.R., Wilson T.O., et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 219 (1994) 112-119
14. Hinson F.L., and Ambrose N.S. Pseudomyxoma peritonei. Br J Surg 85 (1998) 1332-1339
15. Cannistra S.A. Intraperitoneal chemotherapy comes of age. N Engl J Med 354 (2006) 77-79
16. Stewart J.H., Shen P., Russell G.B., Bradley R.F., Hundley J.C., Loggie B.W., et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 13 (2006) 624-634
17. Bradley R.F., Stewart J.H., Russell G., Levine E.A., and Geisinger K.R. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 uniformly treated patients at a single institution, with literature review. Am J Surg Pathol 30 (2006) 551-559
18. Shen P., Levine E.A., Hall J., Case D., Russell G., Fleming R., et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 138 (2003) 26-33
19. Shen P., Hawksworth J., Lovato J., Loggie B.W., Geisinger K.R., Fleming R.A., et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 11 (2004) 178-186
20. Hall J.J., Loggie B.W., Shen P., Beamer S., Case L.D., McQuellon R., et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 8 (2004) 454-463
21. Jacks S.P., Hundley J.C., Shen P., Russell G.B., and Levine E.A. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. J Surg Oncol 91 (2005) 112-117
22. Loggie B.W., Fleming R.A., McQuellon R.P., Russell G.B., Geisinger K.R., and Levine E.A. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67 (2001) 999-1003
23. Levine E.A. Problems of success and problems of failure: recurrent disease after cytoreductive surgery and intraperitoneal chemoperfusion. Ann Surg Oncol 11 (2004) 351-353
24. AJCC. Cancer Staging Manual. 6th edn. (2002), Springer-Verlag, New York, NY
25. Dedrick R.L., and Flessner M.F. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89 (1997) 480-487
26. Dedrick R.L. Interspecies scaling of regional drug delivery. J Pharmacol Sci 75 (1986) 1047-1052
27. Flessner M.F., Dedrick R.L., and Schultz J.S. A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. Am J Physiol 248 (1985) F413-F424
28. Kuzuya T., Yamauchi M., Ito A., Hasegawa M., Hasegawa T., and Nabeshima T. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 46 (1994) 685-689
29. Speyer J.L., Collins J.M., Dedrick R.L., Brennan M.F., Buckpitt A.R., Londer H., et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40 (1980) 567-572
30. Israel V.K., Jiang C., Muggia F.M., Tulpule A., Jeffers S., Leichman L., et al. Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol 37 (1995) 32-38
31. Ozols R.F., Young R.C., Speyer J.L., Sugarbaker P.H., Greene R., Jenkins J., et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42 (1982) 4265-4269
32. Bartlett D.L., Buell J.F., Libutti S.K., Reed E., Lee K.B., Figg W.D., et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 83 (1998) 1251-1261
33. Markman M., and Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118 (1992) 547-550
34. Markman M., Brady M.F., Spirtos N.M., Hanjani P., and Rubin S.C. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group study. J Clin Oncol 16 (1998) 2620-2624
35. Stewart J.H., Shen P., Russell G., Fenstermaker J., McWilliams L., Coldrun F.M., et al. A phase I trial of intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination of colorectal and appendiceal cancers. Ann Surg Oncol 15 (2008) 2137-2145
36. Dikomey E., and Franzke J. Effect of heat on induction and repair of DNA strand breaks in X-irradiated CHO cells. Int J Radiat Biol 61 (1992) 221-233
37. Roti J.L., Kampinga H.H., Malyapa R.S., Wright W.D., vander Waal R.P., and Xu M. Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaperones 3 (1998) 245-255
38. Barlogie B., Corry P.M., and Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40 (1980) 1165-1168
39. Jacquet P., Averbach A., Stuart O.A., Chang D., and Sugarbaker P.H. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism and tissue distribution in a rat model. Cancer Chemother Pharmacol 41 (1998) 147-154
40. Los G., Smals O.A., van Vugt M.J., van der Vlist M., den Englase L., McVie J.G., et al. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 52 (1992) 1252-1258
41. van Ruth S., Acherman Y.I., van de Vijver M.J., Hart A.A., Verwaal V.J., and Zoetmulder F.A. Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol 29 (2003) 682-688
42. Glehen O., Mohamed F., and Gilly F.N. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 5 (2004) 219-228
43. Sugarbaker P.H., and Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 6 (1999) 727-731
44. Witkamp A.J., de Bree E., Kaag M.M., van Slooten G.W., van Coevorden F., and Zoetmulder F.A. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 88 (2001) 458-463
45. Elias D., Laurent S., Antoun S., Duvillard P., Ducreux M., Pocard M., et al. Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy. Gastroenterol Clin Biol 27 (2003) 407-412
46. Deraco M., Baratti D., Inglese M.G., Allaria B., Andreola S., Gavazzi C., et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 11 (2004) 393-398
47. Culliford A.T., Brooks A.D., Sharma S., Saltz L.B., Schwartz G.K., O'Reilly E.M., et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 8 (2001) 787-795
48. Marcus E.A., Weber T.K., Rodriguez-Bigas M.A., Driscoll D., Meropol N.J., and Petrelli N.J. Prognostic factors affecting survival in patients with colorectal carcinomatosis. Cancer Invest 17 (1999) 249-252
49. Glehen O., Kwiakowski F., Sugarbaker P.H., Elias D., Levine E.A., de Simone M., et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22 16 (2004) 3284-3292
50. Esquivel J., Sugarbaker P., Sticca R., Levine E.A., Yan T.D., Alexander R., et al. Consensus statement for cytoreductive surgery and intraperitoneal chemotherapy for colorectal carcinoma. Ann Surg Oncol 14 (2007) 128-133
51. Kelly J.R., and Duggan J.M. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56 (2003) 1-9
52. Pilati P., Rossi C.R., Mocellin S., Foletto M., Scagnet B., Pasetto L., et al. Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol 27 (2001) 125-134
53. Koga S., Hamazoe R., Maeta M., Shimizu N., Murakami A., and Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61 (1988) 232-237
54. Fujimoto S., Takahashi M., Mutou T., Kobayashi K., and Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 85 (1999) 529
55. Yonemura Y., Fujimura T., Nishimura G., Falla R., Sawa T., Katayama K., et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 119 (1996) 437-444
56. Elias D., Blot F., El Otmany A., Antoun S., Lasser P., Boige V., et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92 (2001) 71-76
57. Sayag-Beaujard A.C., Francois Y., Glehen O., Sadeghi-Looyeh B., Bienvenu J., Panteix G., et al. Intraperitoneal chemohyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis. Anticancer Res 19 (1999) 1375-1382
58. Fujimura T., Yonemura Y., Fushida S., Urade M., Takegawa S., Kamata T., et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 65 (1990) 65-71
59. Yu W., Whang I., Chung H.Y., Averbach A., and Sugarbaker P.H. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 25 (2001) 985-990
60. Blair S.L., Chu D.Z.J., and Schwarz R.E. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol 8 (2001) 632-637
61. Hribaschek A., Kuhn R., Pross M., Lippert H., Halangk W., Boltze C., et al. Prophylaxis of peritoneal carcinomatosis in experimental investigations. Int J Colorectal Dis 16 5 (2001) 340-345
62. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
63. MacDonald J.S., Smalley R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-729
64. Kaibara N., Hamazoe R., Iitsuka Y., Maeta M., and Koga S. Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterology 36 (1989) 75-78
65. Tahara M., Ohtsu A., Boku N., Nagashima F., Muto M., Sano Y., et al. Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. Gastric Cancer 4 (2001) 212-218
66. Yonemura Y., Ninomiya I., Kaji M., Sugiyama K., Fujimura K., Sawa T., et al. Prophylaxis with intraperitoneal chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg 19 (1995) 450-455
67. Nomura E., Niki M., Fujii K., Shinohara H., Nishiguchi K., Sonoda T., et al. Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer. Gastric Cancer 4 (2001) 75-82
68. Yan T.D., Black D., Sugarbaker P.H., Zhu J., Yoneura Y., Petrou G., et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14 (2007) 2702-2713
69. Farma J.M., Pingpank J.F., Libutti S.K., Bartlett D.L., Ohl S., Beresneva T., et al. Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. J Gastrointest Surg 9 (2005) 1346-1353
70. Glehen O., Schreiber V., Cotte E., Syag-Beaujard A.C., Osinsky D., Freyer G., et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 139 (2004) 20-26
71. Yonemura Y., Kawamura T., Bandou E., Takahashi S., Sawa T., and Matuski N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthemic peritoneal perfusion. Br J Surg 92 (2005) 370-375
72. Talamonti M.S., Goetz L.H., Rao S., and Joehl R.J. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 137 (2002) 564-570
73. Brucher B.L., Roder J.D., Fink U., Stein H.J., Busch R., and Siewert J.R. Prognostic factors in resected primary small bowel tumors. Digest Surg 15 (1998) 42-51
74. North J.H., and Pack M.S. Malignant tumors of the small intestine: a review of 144 cases. Am Surg 66 (2000) 46-51
75. Frost D.B., Mercado P.D., and Tyrell J.S. Small bowel cancer: a 30-year review. Ann Surg Oncol 1 (1994) 290-295
76. Marchettini P., and Sugarbaker P.H. Mucinous adenocarcinoma of the small bowel with peritoneal seeding. Eur J Surg Oncol 28 (2002) 19-23
77. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
78. Alberts D.S., Lui P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophophamide for stage III ovarian cancer. N Engl J Med 335 (1996) 1950-1955
79. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 1001-1007
80. Armstrong D.K., Bundy B.N., Baergen R., et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group Trial. Proc Am Soc Clin Oncol 21 (2002) 201a (abst 803)
81. Speyer J.L., Beller U., Colombo N., Sorich J., Wernz J.C., Hochster H., et al. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol 8 (1990) 1335-1341
82. Pfeiffer P., Bennedaek O., and Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol 36 (1990) 306-311
83. Helm C.W., Bristow R.E., Kusamura S., Baratti D., and Deraco M. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol 98 (2008) 283-290
84. Lentz S., Miller B.E., Kucera G.L., and Levine E.A. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma. Gynecol Oncol 106 (2007) 207-210
85. Digiorgio A., Naticchioni E., Biacchi D., Sibio S., Accarpio F., Rocco M., et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113 (2008) 315-325
86. Sridhar K., Doria R., Raub W., Thurer R., and Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer 70 (1992) 2969-2979
87. Wagner J., Sleggs C., and Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17 (1960) 260-271
88. Robinson B.W., and Lake R.A. Advances in malignant mesothelioma. N Engl J Med 353 (2005) 1591-1603
89. Chailleux E., Dabouis G., Pioche D., de Lajartre M., de Lajartre A., Rembeaus A., et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 93 (1988) 159-162
90. Pass H., Kranda K., Temeck B., Feuerstein I., and Steinberg S. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 4 (1997) 215-222
91. Janne P. Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer 5 (2003) 98-106
92. Antman K., Shemin R., Ryan L., Klegar K., Osteen R., Herman T., et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 6 (1988) 147-153
93. Ribak J., Lilus R., Suzuki Y., Penner L., and Selikoff I. Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and cause of death. Br J Ind Med 45 (1998) 182-187
94. Trupiano J.K., Geisinger K.M., Willingham M.D., Manders P., Zbieranski N., Case D., et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 17 (2004) 476-481
95. Feldman A.L., Libutti S.K., Pingpank J.F., Bartlett D.L., Beresnev T.H., Mavroukakis S.M., et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21 (2003) 4560-4567
96. Park B.J., Alexander R., Lubutti S.K., Wu P., Royalty D., Kranda K.C., Bartlett D.L., et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion. Ann Surg Oncol 6 (1999) 582-590
97. Cerruto C.A., Brun E.A., Chang D., and Sugarbaker P.H. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med 130 (2006) 1654-1661
98. Yan T., Welch L., Black D., and Sugarbaker P. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18 (2007) 827-834
99. McQuellon R.P., Loggie B.W., Fleming R.A., Russell G.B., Lehman A.B., and Rambo T.D. Quality of life after intraperitoneal hyperthermic chemotherapy (HIPEC) for peritoneal carcinomatosis. Eur J Surg Oncol 27 (2001) 65-73
100. McQuellon R.P., Loggie B.W., Lehman A.B., Russell G.B., Fleming R.A., Shen P., et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 10 (2003) 155-162
101. Alexander HR, Mavroukakis SM, Libutti SK, Pingpank JF, Beresnev TH, Marden S, et al. Impact of tumor resection and intraperitoneal chemotherapy on health related quality of life in patients with peritoneal surface malignancies. Proceedings of the 57th Annual Society of Surgical Oncology Cancer Symposium, 2004.
102. Portilla A.G., Sugarbaker P.H., and Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 23 (1999) 23-29
103. Elias D., Delperro J.R., Sideris L., Benhamou E., Pocard M., Baton O., et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 11 (2004) 518-521